thrombogram

PreclinicalBiologic

IInstitut Cancerologie de l'Ouest

thrombogram is one of 2 biologic programs targeting Oncology Patients. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oncology PatientsRecruiting

Oncology PatientsPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Oncology Patients

#DrugCompanyPhaseTrials

Mekinist

Novartis

Phase 2

1 2

thrombogram

IInstitut Cancerologie de l'Ouest

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

N/ARecruiting

Oncology Patients

NCT06051214

Clinical

Trials by Indication[1]

Oncology Patients1 trial

Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk

Recruiting·IInstitut Cancerologie de l'Ouest·N/A·NCT06051214·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for thrombogram. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — thrombogram compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for thrombogram. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut Cancerologie de l'Ouest company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: IInstitut Cancerologie de l'Ouest

thrombogram

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Oncology Patients1 trial

References

Drug Info

Quick Facts

Related News